What is the recommended dose of levofloxacin (Levaquin) for the treatment of tuberculosis (TB)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dose of Levofloxacin for Tuberculosis Treatment

The recommended dose of levofloxacin for tuberculosis treatment in adults is 750-1,000 mg once daily. 1

Adult Dosing

  • For multidrug-resistant tuberculosis (MDR-TB), levofloxacin should be administered at 750-1,000 mg daily as part of a multidrug regimen 1
  • Levofloxacin is available in tablet formulations (250 mg, 500 mg, 750 mg) and as an aqueous solution (500 mg) for intravenous administration 1, 2
  • For patients with renal insufficiency (creatinine clearance <50 mL/min), the dose should be adjusted to 750-1,000 mg three times weekly instead of daily 1, 2
  • Higher doses up to 1,000 mg/day have shown good tolerability with adequate exposure, while doses >1,000 mg/day resulted in increased adverse events without faster sputum culture conversion 3

Pediatric Dosing

  • For children with MDR-TB, the recommended dose is 15-20 mg/kg/day once daily 1
  • Recent pharmacokinetic studies suggest that higher doses may be required in children to achieve adult-equivalent exposures: from 18 mg/kg/day for younger children to 40 mg/kg/day for older children 1, 4
  • Long-term use of fluoroquinolones in children has traditionally been limited due to concerns about effects on bone and cartilage growth, but most experts agree the drug should be considered for children with MDR-TB 1, 5

Clinical Considerations

  • Levofloxacin is preferred over other fluoroquinolones for treating drug-resistant TB due to its established safety profile with long-term use 1
  • Absorption is significantly decreased when administered with antacids or medications containing divalent cations; levofloxacin should not be given within 2 hours of such medications 1, 2
  • The drug is primarily cleared by the kidneys (80%), requiring dose adjustment in renal insufficiency 1, 2
  • Levofloxacin should be avoided during pregnancy due to potential teratogenic effects 1, 5

Efficacy Considerations

  • Levofloxacin (750 mg/day) has shown similar efficacy to moxifloxacin (400 mg/day) in terms of sputum culture conversion at 3 months of treatment for MDR-TB 6
  • For Mycobacterium tuberculosis isolates with higher minimum inhibitory concentrations (MIC ≥1 mg/L), doses up to 1,500 mg may be required to achieve optimal exposure 7, 8
  • When selecting the dose, consider that the area under the concentration-time curve to MIC ratio (AUC/MIC) of approximately 146-160 is associated with maximal microbial kill 7

Adverse Effects

  • Common adverse effects include gastrointestinal disturbances (nausea, bloating) in 0.5-1.8% of patients 1
  • Neurological effects (dizziness, insomnia, tremulousness, headache) occur in approximately 0.5% of patients 1
  • Cutaneous reactions (rash, pruritus, photosensitivity) occur in 0.2-0.4% of patients 1
  • Higher doses (>1,000 mg/day) are associated with increased frequency of adverse events 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Levofloxacin Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Levofloxacin Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.

American journal of respiratory and critical care medicine, 2013

Research

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.